Anticoagulation prescribing practice following ischaemic strokes in the setting of non-valvular atrial fibrillation

Shuangyue Tan, Cameron Williams, Philip Choi

Research output: Contribution to journalArticleResearchpeer-review

Abstract

It is well established that anticoagulation following an ischaemic stroke in the setting of non-valvular atrial fibrillation is an effective means of secondary prevention. However, there is a lack of a solid evidence base to guide both the agent choice and the optimal timing in which to initiate anticoagulation therapy. The decision is complex, and consideration is required to balance the risks between recurrent strokes and potentially causing or exacerbating parenchymal haemorrhages. A clinical audit was performed at a high-volume primary stroke centre looking at anticoagulation prescribing practices among neurologists. We found apixaban was by far the anticoagulation of choice for non-valvular atrial fibrillation. The median time to anticoagulation initiation was Day 1 post transient ischaemic attack, Day 2 post small infarcts, Day 4 post moderate infarcts and Day 5 post large infarcts.

Original languageEnglish
Pages (from-to)1727-1731
Number of pages5
JournalInternal Medicine Journal
Volume51
Issue number10
DOIs
Publication statusPublished - Oct 2021
Externally publishedYes

Keywords

  • anticoagulation
  • haemorrhage
  • ischaemic
  • secondary prevention
  • stroke
  • timing

Cite this